On January 18, 2021 MonTa Biosciences reported it was awarded with positive feedback from the regulatory agency in Denmark to initiate phase I study on our lead candidate MBS8. The study will start later in Q1 with dosing of solid tumor patients in a dose-escalation study (Press release, MonTa Biosciences, JAN 18, 2021, View Source [SID1234575255]). The primary endpoint is to establish the recommended phase 2 dose level, for which the second part of the study, the expansion stage, will include a larger group of different solid tumor patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!